BET Protein Bromodomain Inhibitor-Based Combinations Are Highly Active Against Post-Myeloproliferative Neoplasm Secondary AML Cells

Leukemia - United Kingdom
doi 10.1038/leu.2016.260
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

HEXIM1 Induction Is Mechanistically Involved in Mediating Anti-Aml Activity of BET Protein Bromodomain Antagonist

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

BET Bromodomain Proteins Are Therapeutic Targets in CRPC

Cancer Discovery
Oncology
2014English

Highly Effective Combination of LSD1 (KDM1A) Antagonist and Pan-Histone Deacetylase Inhibitor Against Human AML Cells

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2014English

Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

Advances in Hematology
Hematology
2012English

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Preclinical Evaluation of the BET Bromodomain Inhibitor BAY 1238097 for the Treatment of Lymphoma

British Journal of Haematology
Hematology
2017English

Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor Against Human Acute Myelogenous Leukemia Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2014English

Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition

Cancer Research
Cancer ResearchOncology
2019English

Coexistence of Myeloproliferative Neoplasm and Plasma-Cell Dyscrasia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy